

# Synthesis and in Vitro Evaluation of 5,6,7,8,9,10-Hexahydro-7,10-iminocyclohept[b]indoles: High-Affinity Ligands for the *N,N'*-Di-*o*-tolylguanidine-Labeled $\sigma$ Binding Site

Richard E. Mewshaw,\*† Ronald G. Sherrill,† Rose M. Mathew,† Carl Kaiser,† Michael A. Bailey,† and E. William Karbon†


Scios-Nova Inc., 6200 Freeport Centre, Baltimore, Maryland 21224-6522

Received August 21, 1992

A series of 5,6,7,8,9,10-hexahydro-7,10-iminocyclo[b]indoles substituted at the 5 and/or 11 positions was synthesized from tropinone. Affinity for  $\sigma$  binding sites was determined using [ $^3$ H]-*N,N'*-di-*o*-tolylguanidine ([ $^3$ H]DTG) and [ $^3$ H]-(+)-3-(3-hydroxyphenyl)-*N*-1-propylpiperidine ([ $^3$ H]-(+)-3-PPP) and for the dopamine D<sub>2</sub> receptor labeled with [ $^3$ H]sulpiride. Nearly all compounds studied in this series possessed a higher affinity for [ $^3$ H]DTG than [ $^3$ H]-(+)-3-PPP-labeled  $\sigma$  sites, suggesting that [ $^3$ H]DTG and [ $^3$ H]-(+)-3-PPP radioligands label pharmacologically distinct  $\sigma$  binding sites, as reported previously. Substitution at the 11 position with side chains containing a four-carbon tether resulted in compounds having the highest affinity for the [ $^3$ H]DTG-labeled  $\sigma$  site. The most potent and selective member of this series was 11-[4-(2-furanyl)butyl]-5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indole (40). Enantioselectivity was investigated by preparing the (+)- and (-)-isomers of 40. These studies revealed that (+)-40 was more potent at the [ $^3$ H]-DTG-labeled  $\sigma$  site whereas (-)-40 had a higher affinity at  $\sigma$  sites labeled with [ $^3$ H]-(+)-3-PPP. Racemic 40 was observed to possess a higher affinity than either of its respective enantiomers at both the [ $^3$ H]DTG- and [ $^3$ H]-(+)-3-PPP-labeled sites, suggesting an allosteric interaction.

$\sigma$  Antagonists have attracted considerable attention due to their therapeutic potential in treating psychiatric and neurodegenerative disorders.<sup>1</sup> Though their physiological role remains largely unknown, recent studies have implicated  $\sigma$  binding sites in the regulation of motor behavior,<sup>2,3</sup> enhancement of neurotransmitter release,<sup>4</sup> smooth-muscle contraction,<sup>4,5</sup> negative modulation of brain phosphoinositide metabolism,<sup>6</sup> and inhibition of neuronal firing rate.<sup>7,8</sup> First postulated by Martin et al.<sup>9</sup> to account for the psychotomimetic effects of *N*-allylnormetazocine (SKF 10,047, 1), recent interest in  $\sigma$  sites has grown because of their ability to bind both typical and atypical antipsychotics. The potential atypical antipsychotic agents rimcazole (2),<sup>10</sup> remoxipride (3),<sup>11</sup> BMY-14802 (4),<sup>12</sup> tioperone (5),<sup>13</sup> cinuperone (6),<sup>14</sup> gevetroline (7),<sup>15</sup> and NPC 16316 (8)<sup>16,17</sup> all possess significant affinity for  $\sigma$  binding sites.<sup>18</sup> Many of these agents have only low affinity for the dopamine D<sub>2</sub> receptor, suggesting that their putative antipsychotic actions are manifested through a non-dopaminergic mechanism.<sup>19</sup> Therefore, these agents might constitute a novel class of neuroleptics which lack many of the undesirable side effects associated with classical D<sub>2</sub> receptor antagonists. In order to further understand the potential therapeutic effects which might be derived from blockade of  $\sigma$  binding sites, there is a need for high-affinity  $\sigma$  ligands whose functional role is not masked by cross-reactivity with other neurotransmitter receptors.

As part of an effort to discover highly selective  $\sigma$  ligands,<sup>16,17</sup> we now report the preparation and in vitro evaluation of a novel series of bridged  $\gamma$ -carbolines (9). Incorporation of an ethylene bridge within the  $\gamma$ -carboline nucleus not only provides a rigid skeleton, but could also impart a conformational impediment, resulting in decreased affinity at other sites, thereby generating highly selective  $\sigma$  ligands. The  $\gamma$ -carboline skeleton was focused



upon for several reasons: (1) chemically, this nucleus possesses a 3-phenylpiperidine moiety embedded within its skeleton, a structural feature suggested as being the primary pharmacophore of  $\sigma$  sites;<sup>20</sup> (2) recently, Glennon et al.<sup>21</sup> provided evidence that the 2-(phenylamino)ethane moiety, also retained in  $\gamma$ -carbolines, serves as the common denominator among a variety of chemically distinct  $\sigma$  ligands; (3) the  $\gamma$ -carboline nucleus (e.g. gevetroline, 7) has been demonstrated to possess affinity for  $\sigma$  binding sites;<sup>1a,18</sup> and (4) the  $\gamma$ -carboline skeleton conforms to some of the criteria for the  $\sigma$  site model proposed by Manallack et al.<sup>22</sup> In this report we discuss structure-activity relationships (SAR) of more than 40 members (13-55) of this series of bridged  $\gamma$ -carbolines with respect to [ $^3$ H]-*N,N'*-di-*o*-tolylguanidine ([ $^3$ H]DTG) and [ $^3$ H]-(+)-3-(3-hydroxyphenyl)-*N*-1-propylpiperidine ([ $^3$ H]-(+)-3-PPP) labeled  $\sigma$  sites. To evaluate selectivity with respect to the dopamine receptor, affinity for the [ $^3$ H]sulpiride-labeled D<sub>2</sub> receptor was determined. Enantioselectivity was investigated by identifying the most potent and selective racemic member of this series, preparing the enantiomers, and determining their affinity for  $\sigma$  and D<sub>2</sub> sites.



## Chemistry

**Synthesis.** Bridged  $\gamma$ -carbolines 13-15 were prepared as illustrated in Scheme I. *N*-(2,2,2-Trichloroethoxy)-nortropinone (11) was derived from commercially available tropinone (10).<sup>23</sup> Reduction of carbamate 11 with zinc in glacial acetic acid afforded nortropinone (12).<sup>23</sup> Fischer indole synthesis (method A) was achieved by initial

\* Department of Medicinal Chemistry.


† Department of Pharmacology.

## Chart I


Scheme I<sup>a</sup>

<sup>a</sup> Reagents and conditions: (a) ClCO<sub>2</sub>CH<sub>2</sub>CCl<sub>3</sub>, K<sub>2</sub>CO<sub>3</sub>; (b) Zn, AcOH; (c) Fischer indole synthesis (method A).


formation of the hydrazone in 2-propanol followed by exposure to HCl gas.<sup>24</sup> The  $\gamma$ -carboline intermediates could be isolated without chromatography. Substitution at the N-11 position was achieved by reacting indoles 13–15 with the appropriate alkyl bromides or chlorides (in the presence of NaI) in DMF as described in the Experimental Section (Scheme II, method B). Substitution at the N-5 position was achieved by initial deprotonation using excess sodium hydride followed by the addition of the appropriate alkyl halide (method C).  $\gamma$ -Carboline 16 (Table I) was prepared directly from tropinone using Fischer indole conditions. Compound 34 (Scheme III)

Scheme II<sup>a</sup>

<sup>a</sup> Reagents and conditions: (a) R<sup>2</sup>X, K<sub>2</sub>CO<sub>3</sub>, DMF (method B); (b) NaH, R<sup>1</sup>X, DMF (method C).


Scheme III<sup>a</sup>

<sup>a</sup> Reagents and conditions: (a) Ph(CH<sub>2</sub>)<sub>4</sub>Br, K<sub>2</sub>CO<sub>3</sub>, DMF; (b) PhNHMeNH<sub>2</sub>, HCl.

Scheme IV<sup>a</sup>


<sup>a</sup> Reagents and conditions: (a) EDC; (b) LAH (method D); (c) 3,4-Cl<sub>2</sub>PhCH<sub>2</sub>COCl; (d) 3,4-Cl<sub>2</sub>PhCH<sub>2</sub>CH<sub>2</sub>OTs (method B).

was prepared by N-alkylation of nortropinone (12) according to general method B, followed by the Fischer indole methodology (method A). Dichloride 55 (Table VII) was prepared from 2-(3,4-dichlorophenyl)ethyl tosylate<sup>25</sup> (available from borohydride reduction of 3,4-dichlorophenylacetic acid followed by tosylation) using method B (Scheme II). Compound 57 was synthesized by DIC coupling of 13 with *N*-(*tert*-butoxycarbonyl)glycine, which was subsequently reduced with lithium aluminum hydride (method D) to afford 58 (Scheme IV).<sup>25</sup> Diamine 58 was acylated with dichlorophenylacetyl chloride to afford 47. Treatment of 58 with 2-(3,4-dichlorophenyl)ethyl tosylate afforded 48. Compound 53 (Table VII) was obtained by


Table I. Binding Affinities of  $\gamma$ -Carbolines<sup>a</sup>


compd <sup>a</sup>	X	R <sup>1</sup>	R <sup>2</sup>	$\sigma$ (IC <sub>50</sub> , nM)		D <sub>2</sub> (K <sub>i</sub> , $\mu$ M) [ <sup>3</sup> H]sulpiride <sup>b</sup>
				[ <sup>3</sup> H]DTG <sup>b</sup>	[ <sup>3</sup> H]-(+)-3-PPP <sup>b</sup>	
13	H	H	H	5000	3590 ( $\pm$ 1410)	>100
14	F	H	H	1473 ( $\pm$ 83)	1212 ( $\pm$ 178)	36.6
15	H	H	Ph	1895	6605	10.0 ( $\pm$ 0.1)
16	H	Me	H	2650 ( $\pm$ 1150)	2005 ( $\pm$ 1095)	16.6 ( $\pm$ 6.0)
17	H	Et	H	3560 ( $\pm$ 1830)	3840	>10.0
18	H	n-Pr	H	1084 ( $\pm$ 43)	1276 ( $\pm$ 724)	11.2 ( $\pm$ 4.1)
19	H	1-butenyl	H	683 ( $\pm$ 284)	1763 ( $\pm$ 306)	0.71
20	F	(CH <sub>2</sub> ) <sub>3</sub> OH	H	317 ( $\pm$ 49)	1382 ( $\pm$ 188)	37.3 ( $\pm$ 12.7)

<sup>a</sup> The compounds presented here are racemates unless indicated. <sup>b</sup> The IC<sub>50</sub> and K<sub>i</sub> binding data for Tables I–VII were generated as described in Experimental Section. All values are the mean of at least two separate determinations followed by  $\pm$ SEM. Values having no error limits are the result of only one experiment.

Scheme V<sup>a</sup>


<sup>a</sup> Reagents and conditions: (a) BrCH<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>OH, (method B); (b) DEAD, PPh<sub>3</sub>, phthalimide; (c) LAH, reflux.

Scheme VI<sup>a</sup>

<sup>a</sup> Reagents and conditions: (a) 3,4-Cl<sub>2</sub>PhOCH<sub>2</sub>COCl, TEA; (b) AlH<sub>3</sub>/THF.

treatment of the  $\gamma$ -carboline 14 with the requisite pyridinylalkyl bromide<sup>15</sup> using general method B. Phthalimides 43 and 45 and isoindoles 44 and 46 were prepared as depicted in Scheme V (methods E and F). Compound 30 was prepared from 13 in two steps as shown in Scheme VI (method G). General methods (A–G) of synthesis, physical, and spectroscopic properties of 13–55 are tabulated in Table VIII.

**Resolution and Determination of Optical Purity.** Racemic 13 was converted to its tartrate salts and resolved

Scheme VII<sup>a</sup>

<sup>a</sup> Reagents and conditions: (a) classical resolution; (b) 2-furanylbutyl bromide, K<sub>2</sub>CO<sub>3</sub>, DMF (method B); (c) EDC, (R)-(-)-methoxyphenylacetic acid; HPLC separation.

through fractional crystallization of the diastereomeric salts from water. An HPLC method was used to estimate the optical purities of enantiomerically enriched samples of 13.<sup>26</sup> Coupling of the liberated free bases with (R)-(+)-O-methylmandelic acid (Aldrich, >99.5  $\pm$  0.5% optically pure) afforded the corresponding O-methylmandeloylamides, 61 and 62 (Scheme VII). Purification by HPLC (reverse phase, C<sub>18</sub> column, 40% acetonitrile–60% water) enabled separation and isolation of the two diastereomeric amides having retention times of approximately 16.6 and 19.3 min.<sup>27</sup> The enantiomeric excess of (-)-13 derived from the classical resolution was determined to be >98% ee, while (+)-13 was observed to be >99% ee. Both enantiomers, (+)-13 and (-)-13, were then N-alkylated to afford (+)-40 and (-)-40, respectively (Scheme VII).

**X-ray Crystallography.** The absolute configuration of (+)-13 and (-)-13 was established by single crystal X-ray crystallographic analysis of (+)-13 derivatized as its (R)-O-methylmandeloylamide 62. The structure was solved according to the direct method<sup>30</sup> and refined by full-matrix






Figure 1. ORTEP drawing of 62 as determined by X-ray analysis.

Table II. Binding Affinities of  $\gamma$ -Carbolines


compd <sup>a</sup>	X	n	$\sigma$ (IC <sub>50</sub> , nM)		D <sub>2</sub> (K <sub>i</sub> , $\mu$ M)
			[ <sup>3</sup> H]DTG <sup>b</sup>	[ <sup>3</sup> H]-(+)-3-PPP <sup>b</sup>	
21	F	1	86 ( $\pm$ 14)	908 ( $\pm$ 222)	2.42 ( $\pm$ 1.32)
22	H	1	345 ( $\pm$ 85)	2750 ( $\pm$ 550)	3.65 ( $\pm$ 0.25)
23	H	2	234 ( $\pm$ 6)	1280 ( $\pm$ 300)	0.84
24	H	3	81 ( $\pm$ 13)	368 ( $\pm$ 60)	2.6
25	H	4	25 ( $\pm$ 3)	114 ( $\pm$ 25)	0.733
26	H	5	107 ( $\pm$ 59)	348 ( $\pm$ 70)	0.677 ( $\pm$ 0.164)
27	F	4	38 ( $\pm$ 3)	178 ( $\pm$ 16)	0.769 ( $\pm$ 0.208)

<sup>a,b</sup> See footnotes of Table I.Table III. Binding Affinities of  $\gamma$ -Carbolines


compd <sup>a</sup>	X	Y	n	$\sigma$ (IC <sub>50</sub> , nM)		D <sub>2</sub> (K <sub>i</sub> , $\mu$ M)
				[ <sup>3</sup> H]DTG <sup>b</sup>	[ <sup>3</sup> H]-(+)-3-PPP <sup>b</sup>	
28	H	H	2	110 ( $\pm$ 8)	534 ( $\pm$ 40)	2.60
29	H	Cl	2	251 ( $\pm$ 28)	4876 ( $\pm$ 2308)	0.53
30	Cl	Cl	2	400 ( $\pm$ 93)	782 ( $\pm$ 12)	0.65
31	H	H	3	132 ( $\pm$ 16)	262 ( $\pm$ 18)	1.28 ( $\pm$ 0.26)
32	H	F	3	55 ( $\pm$ 9)	148 ( $\pm$ 12)	2.10 ( $\pm$ 0.77)
33	H	H	4	88 ( $\pm$ 15)	205 ( $\pm$ 57)	0.10


<sup>a,b</sup> See footnotes of Table I.

least squares and difference Fourier methods. The oxygen and nitrogen atoms were refined anisotropically. The carbon atoms were refined isotropically because of the low reflection to parameter ratio. The hydrogen atom attached to the nitrogen atom was located from a difference Fourier map and refined isotropically. The positions of the remaining hydrogen atoms were calculated assuming ideal geometries. The space group was determined to be  $P2_12_12_1$ . The cell parameters and characteristics are shown in Table IX. The ORTEP drawing of 62 is shown in Figure 1. As a consequence, the stereocenters of (+)-13 and (-)-13 are 7*S*,10*R* and 7*R*,10*S*, respectively.


## Results and Discussion





**$\sigma$  Site Affinity.** All compounds were examined for their affinity at  $\sigma$  sites labeled with [<sup>3</sup>H]DTG and [<sup>3</sup>H]-(+)-

Table IV. Binding Affinities of N-Substituted Derivatives of 25




compd <sup>a</sup>	R	$\sigma$ (IC <sub>50</sub> , nM)		D <sub>2</sub> (K <sub>i</sub> , $\mu$ M)
		[ <sup>3</sup> H]DTG <sup>b</sup>	[ <sup>3</sup> H]-(+)-3-PPP <sup>b</sup>	
25	H	25 ( $\pm$ 3)	114 ( $\pm$ 25)	0.73 ( $\pm$ 0.01)
34	Me	116 ( $\pm$ 6)	281 ( $\pm$ 99)	1.82 ( $\pm$ 0.08)
35	<i>i</i> -Pr	231 ( $\pm$ 35)	705 ( $\pm$ 20)	2.64 ( $\pm$ 0.27)
36	Ph	212 ( $\pm$ 14)	1210 ( $\pm$ 150)	1.57 ( $\pm$ 0.34)
37	Bn	267 ( $\pm$ 87)	396 ( $\pm$ 92)	1.83 ( $\pm$ 0.14)

<sup>a,b</sup> See footnotes of Table I.Table V. Binding Affinities of  $\gamma$ -Carbolines


compd <sup>a</sup>	X	$\sigma$ (IC <sub>50</sub> , nM)		D <sub>2</sub> (K <sub>i</sub> , $\mu$ M)
		[ <sup>3</sup> H]DTG <sup>b</sup>	[ <sup>3</sup> H]-(+)-3-PPP <sup>b</sup>	
25	Ph	25 ( $\pm$ 3)	114 ( $\pm$ 25)	0.73 ( $\pm$ 0.01)
38	4-FC <sub>6</sub> H <sub>4</sub>	37 ( $\pm$ 8)	107 ( $\pm$ 5)	1.16 ( $\pm$ 0.01)
39		21 ( $\pm$ 6)	98 ( $\pm$ 24)	0.62 ( $\pm$ 0.11)
40 <sup>c</sup>		28 ( $\pm$ 7)	105 ( $\pm$ 8)	1.27 ( $\pm$ 0.39)
41 <sup>c</sup>		66 ( $\pm$ 29)	136 ( $\pm$ 54)	2.23 ( $\pm$ 0.77)
42		54 ( $\pm$ 4)	988 ( $\pm$ 152)	3.00 ( $\pm$ 0.91)

<sup>a,b</sup> See footnotes of Table I. <sup>c</sup> See refs 40 and 41.

Table VI. Binding Affinities of Enantiomers of 40



compd	$\sigma$ (IC <sub>50</sub> , nM)		D <sub>2</sub> (K <sub>i</sub> , $\mu$ M)
	[ <sup>3</sup> H]DTG <sup>a</sup>	[ <sup>3</sup> H]-(+)-3-PPP <sup>a</sup>	
( $\pm$ )-40	28 ( $\pm$ 7)	105 ( $\pm$ 8)	1.27 ( $\pm$ 0.39)
(+)-40 <sup>b</sup>	46 ( $\pm$ 13)	482 ( $\pm$ 51)	0.33 ( $\pm$ 0.10)
(-)-40 <sup>c</sup>	170 ( $\pm$ 12)	108 ( $\pm$ 1)	3.15 ( $\pm$ 0.13)

<sup>a</sup> The IC<sub>50</sub> and K<sub>i</sub> binding data were generated as described in Experimental Section. All values are the mean of at least three separate determinations. <sup>b</sup> [ $\alpha$ ]<sub>D</sub><sup>24</sup> +11° (c = 1, CH<sub>2</sub>Cl<sub>2</sub>). <sup>c</sup> [ $\alpha$ ]<sub>D</sub><sup>24</sup> -10° (c = 1, CH<sub>2</sub>Cl<sub>2</sub>).

3-PPP in guinea pig brain membranes (Tables I–VI). The unsubstituted  $\gamma$ -carbolines and lower-alkyl substituted  $\gamma$ -carbolines (13–20, Table I) had little affinity for the  $\sigma$  sites. Affinity increased dramatically upon substitution of the 11 position with phenylalkyl side chains (Table II). Increasing the length of the alkyl spacer between the basic amine and the phenyl group from one to four methylene units (22–25) resulted in a progressive increase in affinity. However, when the chain length was increased further by

Table VII. Binding Affinities of Miscellaneous  $\gamma$ -Carboline Derivatives

compd <sup>a</sup>	R <sup>1</sup>	R <sup>2</sup>	X	$\sigma$ (IC <sub>50</sub> , nM)		D <sub>2</sub> (K <sub>i</sub> , $\mu$ M) [ <sup>3</sup> H]sulpiride <sup>b</sup>
				[ <sup>3</sup> H]DTG <sup>b</sup>	[ <sup>3</sup> H]-(+)-3-PPP <sup>b</sup>	
43		H	H	8085 ( $\pm$ 1915)	>10000	52.1
44		H	H	141 ( $\pm$ 22)	85 ( $\pm$ 18)	2.0 ( $\pm$ 0.2)
45		H	F	836 ( $\pm$ 333)	3332 ( $\pm$ 1808)	12.3 ( $\pm$ 1.7)
46		H	F	54 ( $\pm$ 18)	76 ( $\pm$ 20)	1.78 ( $\pm$ 0.62)
47		H	H	1612 ( $\pm$ 660)	>10000	3.79
48		H	H	509 ( $\pm$ 63)	474 ( $\pm$ 140)	2.53 ( $\pm$ 0.15)
49		H	H	129 ( $\pm$ 55)	283 ( $\pm$ 50)	0.27 ( $\pm$ 0.01)
50	<i>t</i> -CH <sub>2</sub> CH=CHPh	H	H	133 ( $\pm$ 9)	517 ( $\pm$ 119)	2.46
51	(CH <sub>2</sub> ) <sub>2</sub> CHPh <sub>2</sub>	H	H	1483 ( $\pm$ 34)	4007 ( $\pm$ 1599)	4.52
52		H	F	3044 ( $\pm$ 574)	>10000	5.31 ( $\pm$ 0.98)
53		H	F	44 ( $\pm$ 11)	114 ( $\pm$ 10)	12.2 ( $\pm$ 4.7)
54	(CH <sub>2</sub> ) <sub>2</sub> Ph	Bn	H	482 ( $\pm$ 72)	487 ( $\pm$ 182)	1.62
55		H	H	702 ( $\pm$ 66)	>10000	3.43
7	gevetroline			182 ( $\pm$ 19)	282 ( $\pm$ 12)	0.006 ( $\pm$ 0.002)

<sup>a,b</sup> See footnotes of Table I.

one methylene unit (e.g. 26), affinity decreased. Very little effect on affinity was observed when an oxygen atom was incorporated in the side-chain spacer between the phenyl group and amine (24 vs 28, 25 vs 31, 26 vs 33, 27 vs 32). In all cases, substitution of chlorine in the phenyl rings resulted in a decrease in affinity (23 vs 55, 24 vs 29 or 30). Substituting fluorine for hydrogen (31 vs 32) resulted in a 2-fold increase in affinity in the phenoxy series (Table III). However, this was not observed in the phenylalkyl-substituted series (25 vs 27). Substitution on the indole nitrogen in all cases (25 vs 34–37, Table IV) resulted in lower affinity ligands. Compounds 43, 45, and 47 all had lower affinity than their respective reduced analogues, 44, 46, and 48 (Table VII). These results support the earlier suggestion that binding sites for two basic nitrogens may exist within the  $\sigma$  site.<sup>25</sup> Incorporation of the previously reported<sup>25</sup>  $\sigma$  potent side chains [e.g. (3,4-dichlorophenyl)-

acetamide and 2-(3,4-dichlorophenyl)ethyl groups] into the  $\gamma$ -carboline nucleus resulted in ligands having low affinity for the  $\sigma$  sites. The conformationally restricted gevetroline analogue 53 (Table VII) had a 4- and 2.5-fold higher affinity than gevetroline (7) at [<sup>3</sup>H]DTG and [<sup>3</sup>H]-(+)-3-PPP sites, respectively. Compounds possessing the highest affinity at  $\sigma$  binding sites (Table V) all have in common a four-carbon tether; however, very little difference in affinity was observed for these derivatives (Table V).

**$\sigma$ /D<sub>2</sub> Selectivity.** The bridged  $\gamma$ -carboline series described above was observed to have a higher affinity for the [<sup>3</sup>H]DTG-labeled  $\sigma$  binding site than the dopamine D<sub>2</sub> receptor. However, lower selectivity was observed between the [<sup>3</sup>H]-(+)-3-PPP-labeled  $\sigma$  binding site and the D<sub>2</sub> receptor. In fact, compound 33 had higher affinity for the D<sub>2</sub> receptor (K<sub>i</sub> = 100 nM) than the [<sup>3</sup>H]-(+)-3-

PPP labeled site ( $IC_{50} = 205$  nM). Data presented in Table III indicate that as the chain length increases between the basic nitrogen and phenoxy group, so too does  $D_2$  affinity (i.e.  $33 > 31 > 28$ ). Though incorporation of an ethylene bridge (e.g. 53) into the  $\gamma$ -carboline skeleton of gevetroline (7) increased affinity at both  $\sigma$  binding sites, potency at the  $D_2$  receptor was greatly reduced ( $K_i = 12.2$   $\mu$ M vs 6.0 nM).

**$\sigma$  Site Selectivity and Enantioselectivity.** Several lines of evidence now suggest the existence of pharmacologically distinct  $\sigma$  binding sites.<sup>31-35</sup> One of these sites (termed  $\sigma_1$ ) is preferentially labeled by [ $^3$ H]-(+)-3-PPP and [ $^3$ H]-(+)-pentazocine, exhibits high affinity for (+)-benzomorphans and dextromethorphan, and is allosterically modulated by phenytoin and guanine nucleotides.<sup>36</sup> The other binding site (termed  $\sigma_2$ ) can be selectively labeled by [ $^3$ H]DTG once the  $\sigma_1$  site is blocked by pentazocine, exhibits low affinity for (+)-benzomorphans and dextromethorphan, and is insensitive to phenytoin and guanine nucleotides.<sup>36</sup> A  $\sigma$  binding site with pharmacological properties similar to those of the  $\sigma_2$  binding site in brain has been identified on PC12 cells and in rat liver membranes.<sup>31</sup> In general, most  $\sigma$  ligands reported so far possess higher affinity for the [ $^3$ H]-(+)-3-PPP ( $\sigma_1$ ) binding site.<sup>1a,33,34</sup> However, as indicated in Tables I–VII, virtually all the  $\gamma$ -carbolines in this series exhibited higher affinity for the  $\sigma$  binding site labeled with [ $^3$ H]DTG than [ $^3$ H]-(+)-3-PPP, suggesting that this series of  $\gamma$ -carbolines has a higher affinity for the  $\sigma_2$  binding site. Highest selectivity for the [ $^3$ H]DTG binding site, observed for 29 (19-fold), can be attributed to the detrimental effect of the chlorine atom (28 vs 29, Table III) on the [ $^3$ H]-(+)-3-PPP-labeled site. The reduced sensitivity of the [ $^3$ H]-(+)-3-PPP binding site to this series of compounds supports the notion that [ $^3$ H]DTG and [ $^3$ H]-(+)-3-PPP are labeling pharmacologically distinct  $\sigma$  binding sites.

Recent investigations have shown that enantioselectivity is observed within the benzomorphan class of  $\sigma$  ligands.<sup>1a,33,34</sup> Furthermore, the (+)-isomers of pentazocine, cyclazocine, SKF 10047, and 3-PPP possessed a higher affinity for the [ $^3$ H]-(+)-3-PPP labeled site than their respective (–)-isomers. However, these  $\sigma$  ligands retained a reduced enantioselectivity for the [ $^3$ H]DTG labeled site. In order to further discern the binding properties within this class of  $\gamma$ -carbolines, enantioselectivity was investigated by examining one of the most potent and selective  $\sigma$  ligands in Table V (i.e. 40). As shown in Table VI, (+)-40 had a higher affinity for the [ $^3$ H]DTG-labeled binding site, whereas (–)-40 possessed a higher affinity for the [ $^3$ H]-(+)-3-PPP-labeled site. Thus, an opposite stereoselectivity was observed at the [ $^3$ H]DTG- and [ $^3$ H]-(+)-3-PPP-labeled binding sites, providing further evidence for the existence of pharmacologically distinct  $\sigma$  binding sites. Interestingly, ( $\pm$ )-40 had equal or slightly higher affinity for both [ $^3$ H]DTG- and [ $^3$ H]-(+)-3-PPP-labeled sites than either one of its enantiomers. An allosteric-type of model could explain our results, in which both enantiomers of 40 are capable of increasing each other's affinity for the [ $^3$ H]-DTG- and [ $^3$ H]-(+)-3-PPP-labeled  $\sigma$  sites. Allosteric coupling effects have been reported to be associated with the  $\sigma$  binding site.<sup>1a,33,34</sup> Rothman and co-workers recently reported that several  $\sigma$  ligands are capable of accelerating the dissociation of [ $^3$ H]DTG from its binding sites and termed this conceptualization the "pseudoallosteric mod-

el".<sup>37</sup> Additional experiments are necessary to more clearly define this phenomenon.

In summary, a novel series of rigid  $\gamma$ -carbolines has been identified. This series includes some of the most potent ligands for the [ $^3$ H]DTG-labeled  $\sigma$  binding site reported to date. The results from this radioligand binding study provide further evidence to support the existence of  $\sigma$  binding site subtypes. Comparison of the present series of conformationally rigid compounds with other  $\sigma$  ligands may provide insight into the requirements for the development of more potent and selective  $\sigma_2$  ligands to probe further the functional role of this binding site.

## Experimental Section

**Chemistry.** Melting points were determined using a Thomas-Hoover capillary melting point apparatus and are uncorrected.  $^1$ H NMR and  $^{13}$ C spectra were recorded with a General Electric QE300 spectrometer or Bruker AC 400-MHz spectrometer using tetramethylsilane as an internal standard. IR spectra were obtained on a Beckman FT 1300 spectrophotometer. Elemental analyses were performed by Atlantic Microlab, Inc. of Atlanta, GA. Specific rotation determinations at the sodium D line were obtained on a Perkin-Elmer 241-MC polarimeter at 24 °C. Single-crystal X-ray analysis of 62 was carried out by the Molecular Structure Corp. of The Woodlands, TX. Thin-layer chromatography (TLC) was performed using fluorescent 0.25-mm silica gel plates (Merck, Kieselgel 60 F-254). Tropinone was purchased from Lancaster Synthesis Inc. Many of the compounds described in this paper, particularly oxalate salts, were obtained as partial hydrates despite drying in vacuo. Hydration was confirmed by Karl Fischer determination in several cases. Shown below is an example of each method described in Table VIII.

**Nortropinone Hydrochloride (12).**<sup>23</sup> To a slurry of zinc dust (64.7 g, 0.99 g-atom) in glacial acetic acid (50 mL) under argon at 60 °C was slowly added dropwise over 1 h a solution of 2,2,2-trichlorocarboxynortropinone<sup>23</sup> (75 g, 0.25 mol) in glacial acetic acid (100 mL). The temperature was maintained above 60 °C during the course of the addition by the heat of reaction. After the addition was completed, the reaction temperature was maintained at 60 °C until gas evolution had ceased. The reaction mixture was allowed to stir at room temperature and then it was filtered using a small quantity of acetic acid. The filter cake was washed with water, and the filtrates were combined and passed slowly through a column packed with 375 g of Amberlyst 15 (prewashed with water). The column was washed sequentially with water, methanol, and finally 10% aqueous ammonium hydroxide in methanol. The combined eluents were concentrated in vacuo to an oil which was dissolved in methylene chloride, dried over anhydrous sodium sulfate, filtered, and concentrated to an oil. The oil was dissolved in ether (100 mL), and 1 N HCl in ether (500 mL) was added dropwise. After the resulting slurry was stirred vigorously for 15 min, it was filtered and dried under vacuum to afford colorless crystals: yield 31.4 g (78%); mp 192–199 °C dec (lit.<sup>23</sup> mp 190–199 °C dec).

**General Methods. Method A. 5,6,7,8,9,10-Hexahydro-7,10-iminocyclohept[b]indole Fumarate (13).** Nortropinone hydrochloride (10.0 g, 61.9 mmol) and phenylhydrazine (7.7 g, 71.2 mmol) were heated for 30 min at reflux in anhydrous 2-propanol (175 mL). The reaction mixture was allowed to cool to ambient temperature and then saturated with hydrogen chloride and heated to reflux for an additional 10 h. The resulting solution was concentrated under reduced pressure to give a dark residue which was dissolved in methanol. Amberlite IRA-400 resin (prewashed with methanol) was added to pH > 10. The mixture was filtered and the resin washed with hot methanol. The filtrate was concentrated in vacuo to give an oil which was diluted with methanol. The resulting solution was heated to reflux and treated with 15 g of Norite activated charcoal. After filtration through a pad of diatomaceous earth, the pad was washed with hot methanol, followed by hot 2-propanol. Concentration of the filtrate in vacuo afforded an oil. The crude product was diluted with methylene chloride (50 mL) and stored in a freezer overnight. The precipitate was filtered, washed with methylene chloride

Table VIII. Physical and Chemical Data

compd	formula <sup>a</sup>	mp, °C	recryst solvent	method <sup>b</sup>	% yield
13	C <sub>13</sub> H <sub>14</sub> N <sub>2</sub> ·0.5C <sub>4</sub> H <sub>4</sub> O <sub>4</sub>	208–209 <sup>i</sup>	EtOH	A	69
14	C <sub>13</sub> H <sub>13</sub> FN <sub>2</sub> ·C <sub>4</sub> H <sub>4</sub> O <sub>4</sub> <sup>c</sup>	145 <sup>i</sup>	THF	A	75
15	C <sub>19</sub> H <sub>18</sub> N <sub>2</sub> ·HCl <sup>c</sup>	262–264 <sup>i</sup>	H <sub>2</sub> O	A	66
16	C <sub>14</sub> H <sub>16</sub> N <sub>2</sub> ·0.1H <sub>2</sub> O	158–161	Et <sub>2</sub> O	A	32
17	C <sub>15</sub> H <sub>18</sub> N <sub>2</sub> ·C <sub>2</sub> H <sub>2</sub> O <sub>4</sub> <sup>c</sup>	88–92 <sup>i</sup>	EtOH/Et <sub>2</sub> O	B	82
18	C <sub>16</sub> H <sub>20</sub> N <sub>2</sub> ·C <sub>2</sub> H <sub>2</sub> O <sub>4</sub>	187–188 <sup>i</sup>	acetone	B	83
19	C <sub>17</sub> H <sub>20</sub> N <sub>2</sub> ·C <sub>2</sub> H <sub>2</sub> O <sub>4</sub>	179.5–182	EtOH	B	68
20	C <sub>16</sub> H <sub>19</sub> FN <sub>2</sub> ·O·C <sub>2</sub> H <sub>2</sub> O <sub>4</sub>	158–159.5	acetone	B	75
21	C <sub>20</sub> H <sub>19</sub> FN <sub>2</sub>	170–172	EtOAc/hex	B	69
22	C <sub>20</sub> H <sub>20</sub> N <sub>2</sub>	198–199.5	EtOAc	B	72
23	C <sub>21</sub> H <sub>22</sub> N <sub>2</sub> ·C <sub>2</sub> H <sub>2</sub> O <sub>4</sub>	176–181 <sup>i</sup>	THF	B	82
24	C <sub>22</sub> H <sub>24</sub> N <sub>2</sub> ·C <sub>2</sub> H <sub>2</sub> O <sub>4</sub> <sup>d</sup>	149–152	THF	B	64
25	C <sub>23</sub> H <sub>26</sub> N <sub>2</sub> ·HCl <sup>c</sup>	<sup>h</sup>	Et <sub>2</sub> O	B	88
26	C <sub>24</sub> H <sub>28</sub> N <sub>2</sub> ·C <sub>2</sub> H <sub>2</sub> O <sub>4</sub>	106–109	THF	B	75
27	C <sub>23</sub> H <sub>25</sub> FN <sub>2</sub> ·C <sub>2</sub> H <sub>2</sub> O <sub>4</sub>	161–161.5	THF/EtOAc	B	58
28	C <sub>21</sub> H <sub>22</sub> N <sub>2</sub> ·O·C <sub>2</sub> H <sub>2</sub> O <sub>4</sub>	169–170.5	THF	B	50
29	C <sub>21</sub> H <sub>21</sub> ClN <sub>2</sub> ·O·C <sub>4</sub> H <sub>4</sub> O <sub>4</sub>	198–199 <sup>i</sup>	THF	B	49
30	C <sub>21</sub> H <sub>20</sub> Cl <sub>2</sub> N <sub>2</sub> ·O·C <sub>4</sub> H <sub>4</sub> O <sub>4</sub>	182–183	acetone	G	60
31	C <sub>22</sub> H <sub>24</sub> N <sub>2</sub> ·O·C <sub>2</sub> H <sub>2</sub> O <sub>4</sub>	164–167 <sup>i</sup>	THF	B	56
32	C <sub>22</sub> H <sub>23</sub> FN <sub>2</sub> ·O·C <sub>2</sub> H <sub>2</sub> O <sub>4</sub>	174–175.5 <sup>i</sup>	EtOH	B	84
33	C <sub>23</sub> H <sub>26</sub> N <sub>2</sub> ·O·C <sub>4</sub> H <sub>4</sub> O <sub>4</sub>	135–138	THF	B	93
34	C <sub>24</sub> H <sub>28</sub> N <sub>2</sub> ·C <sub>2</sub> H <sub>2</sub> O <sub>4</sub>	170–171	IPA	A	50
35	C <sub>26</sub> H <sub>32</sub> N <sub>2</sub> ·C <sub>2</sub> H <sub>2</sub> O <sub>4</sub>	178–180	acetone	C	58
36	C <sub>29</sub> H <sub>30</sub> N <sub>2</sub> ·C <sub>2</sub> H <sub>2</sub> O <sub>4</sub>	131–132	THF/Et <sub>2</sub> O	B	93
37	C <sub>30</sub> H <sub>32</sub> N <sub>2</sub> ·1.5C <sub>2</sub> H <sub>2</sub> O <sub>4</sub>	181–183	IPA	C	34
38	C <sub>23</sub> H <sub>25</sub> FN <sub>2</sub> ·C <sub>2</sub> H <sub>2</sub> O <sub>4</sub>	120–121	acetone	B	56
39	C <sub>21</sub> H <sub>24</sub> N <sub>2</sub> S·C <sub>2</sub> H <sub>2</sub> O <sub>4</sub> <sup>c</sup>	118–120	THF	B	74
40	C <sub>21</sub> H <sub>24</sub> N <sub>2</sub> ·O·C <sub>2</sub> H <sub>2</sub> O <sub>4</sub> <sup>c</sup>	86–88 <sup>i</sup>	THF/Et <sub>2</sub> O	B	66
(+)-40	C <sub>21</sub> H <sub>24</sub> N <sub>2</sub> ·O·C <sub>2</sub> H <sub>2</sub> O <sub>4</sub> <sup>i</sup>	108–112	THF	B	58
(-)-40	C <sub>21</sub> H <sub>24</sub> N <sub>2</sub> ·O·C <sub>2</sub> H <sub>2</sub> O <sub>4</sub>	108–112	THF	B	54
41	C <sub>20</sub> H <sub>23</sub> N <sub>3</sub> S·2C <sub>2</sub> H <sub>2</sub> O <sub>4</sub> <sup>e</sup>	54–58 <sup>i</sup>	EtOH/Et <sub>2</sub> O	B	58
42	C <sub>26</sub> H <sub>33</sub> N <sub>3</sub> O <sub>2</sub> <sup>c</sup>	149–152	EtOAc	B	51
43	C <sub>23</sub> H <sub>21</sub> N <sub>3</sub> ·O·C <sub>2</sub> H <sub>2</sub> O <sub>4</sub> <sup>c</sup>	163–165 <sup>i</sup>	THF	E	82
44	C <sub>23</sub> H <sub>25</sub> N <sub>3</sub> ·1.5C <sub>2</sub> H <sub>2</sub> O <sub>4</sub> <sup>c</sup>	154–158 <sup>i</sup>	EtOH	F	35
45	C <sub>24</sub> H <sub>22</sub> FN <sub>3</sub> O <sub>2</sub> ·C <sub>2</sub> H <sub>2</sub> O <sub>4</sub>	155–160	IPA	E	82
46	C <sub>24</sub> H <sub>26</sub> N <sub>3</sub> F·1.5C <sub>2</sub> H <sub>2</sub> O <sub>4</sub> <sup>d</sup>	162–165	EtOH	F	88
47	C <sub>24</sub> H <sub>25</sub> Cl <sub>2</sub> N <sub>3</sub> ·O·C <sub>2</sub> H <sub>2</sub> O <sub>4</sub>	132–137	EtOAc/THF	D	97
48	C <sub>24</sub> H <sub>27</sub> Cl <sub>2</sub> N <sub>3</sub> ·2C <sub>2</sub> H <sub>2</sub> O <sub>4</sub>	137–139 <sup>i</sup>	THF	B	72
49	C <sub>23</sub> H <sub>23</sub> FN <sub>2</sub> O	166–168	Et <sub>2</sub> O	B	58
50	C <sub>22</sub> H <sub>22</sub> N <sub>2</sub> <sup>i</sup>	211–212	acetone	B	80
51	C <sub>28</sub> H <sub>28</sub> N <sub>2</sub> ·HCl	202–203	EtOAc	B	86
52	C <sub>20</sub> H <sub>18</sub> FN <sub>2</sub> ·C <sub>2</sub> H <sub>2</sub> O <sub>4</sub> <sup>f</sup>	132–138	IPA	B	52
53	C <sub>21</sub> H <sub>22</sub> FN <sub>3</sub> ·C <sub>4</sub> H <sub>4</sub> O <sub>4</sub>	154–156	acetone	B	67
54	C <sub>28</sub> H <sub>28</sub> N <sub>2</sub> ·C <sub>2</sub> H <sub>2</sub> O <sub>4</sub> <sup>i</sup>	170–172	THF	C	37
55	C <sub>21</sub> H <sub>20</sub> Cl <sub>2</sub> N <sub>2</sub> ·C <sub>2</sub> H <sub>2</sub> O <sub>4</sub>	183.5–184.5 <sup>i</sup>	acetone	B	67

<sup>a</sup> C<sub>4</sub>H<sub>4</sub>O<sub>4</sub> represents fumaric acid, C<sub>2</sub>H<sub>2</sub>O<sub>4</sub> represents oxalic acid. All new compounds analyzed correctly ( $\pm 0.4\%$ ) for C, H, N. <sup>b</sup> Method of preparation; see Experimental Section. <sup>c</sup> Hemihydrate. <sup>d</sup> Hydrate. <sup>e</sup> Sesquihydrate. <sup>f</sup> 0.25-Hydrate. <sup>g</sup> 0.5i-PrOH. <sup>h</sup> Amorphous solid. <sup>i</sup> Decomposes.

(25 mL), and dried to afford a yellow solid; yield 8.4 g (69%). An analytical sample was prepared as the fumarate salt in THF and recrystallized from ethanol to afford a white crystalline solid: mp 208–209 °C dec; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>)  $\delta$  1.63 (1 H, m), 1.90 (1 H, m), 2.15–2.19 (2 H, m), 2.68 (1 H, d, *J* = 16.4 Hz), 3.31 (1 H, dd, *J* = 16.6, 4 Hz), 4.20 (1 H, bs), 4.84 (1 H, d, *J* = 4 Hz), 6.35 (1 H, s, fumarate), 6.93–7.04 (2 H, m), 7.28 (1 H, d, *J* = 8 Hz), 7.46 (1 H, d, *J* = 8 Hz), 11.10 (1 H, s). Anal. (C<sub>13</sub>H<sub>14</sub>N<sub>2</sub>·0.5C<sub>4</sub>H<sub>4</sub>O<sub>4</sub>) C, H, N.

**2-Fluoro-5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indole fumarate (14)** was similarly prepared using *p*-fluorophenylhydrazine to afford the free base as a yellow crystalline solid: yield 75%; mp 188–189 °C (free base, CH<sub>2</sub>Cl<sub>2</sub>). An analytical sample was prepared as the white solid fumarate salt: mp 145 °C dec (fumarate, amorphous solid); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, fumarate)  $\delta$  1.71–1.78 (1 H, m), 1.95–1.98 (1 H, m), 2.19–2.22 (2 H, m), 2.79 (1 H, d, *J* = 17 Hz), 3.36 (1 H, dd, *J* = 17, 4.4 Hz), 4.33 (1 H, bs), 5.00 (1 H, d, *J* = 4.2 Hz), 6.43 (2 H, s, CH = CH), 6.84–6.91 (1 H, m), 7.28–7.36 (2 H, m), 11.30 (1 H, s); <sup>13</sup>C NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  29.38, 33.63, 36.66, 51.00, 52.29, 101.57 (d, *J* = 23.2 Hz), 107.21 (d, *J* = 25.7 Hz), 111.35 (d, *J* = 9.9 Hz), 116.72 (d, *J* = 4.6 Hz), 124.68 (d, *J* = 10.0 Hz), 132.03, 133.52, 156.70 (d, *J* = 230.3 Hz). Anal. (C<sub>13</sub>H<sub>13</sub>FN<sub>2</sub>·C<sub>4</sub>H<sub>4</sub>O<sub>4</sub>·0.5H<sub>2</sub>O) C, H, N.

**Method B. General Procedure for N-Alkylation of  $\gamma$ -Carbolines 13–15.** 11-(4-Phenoxybutyl)-5,6,7,8,9,10-hexahydro-

**dro-7,10-iminocyclohept[b]indole (33).** 1-Bromo-4-phenoxybutane (694 mg, 3.03 mmol), 13 (400 mg, 2.02 mmol), potassium carbonate (418 mg, 3.03 mmol), and DMF (5 mL) are stirred together at 60 °C for 4 h. The mixture was cooled and diluted with 200 mL of ethyl acetate and 30 mL of water. The organic layer was separated, washed with 20 mL of saturated aqueous brine solution, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. Flash chromatography (methylene chloride/methanol, 95:5) afforded a tan oil; yield 610 mg (91%). An oxalate was prepared in THF (Table VIII). (Note: A catalytic amount of potassium iodide was added when using alkyl chlorides or tosylates as alkylating agents.)

**Method C. General Procedure for Alkylation of Indole Nitrogen.** 11-(4-Phenylbutyl)-5,6,7,8,9,10-hexahydro-5-isopropyl-7,10-iminocyclohept[b]indole (35). A mixture of 11-(4-phenylbutyl)-5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indole (25) (670 mg, 2.03 mmol), sodium hydride (200 mg), and 20 mL of dimethylformamide was stirred for 30 min at room temperature. After isopropyl bromide (3 equiv) was added, the mixture was stirred for 4 h. The reaction was diluted with ethyl acetate (200 mL) and water (50 mL). The organic layer was washed with water (2  $\times$  30 mL), dried over anhydrous sodium sulfate, concentrated, and chromatographed (flash silica, CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH, 95:5) to afford a tan oil; yield 440 mg (58%). An oxalate was prepared in acetone; mp 178–180 °C (Table VIII).

**Table IX.** Cell Parameters and Experimental Details X-ray Analysis of 62

Crystal Data	
empirical formula	C <sub>22</sub> H <sub>22</sub> N <sub>2</sub> O <sub>2</sub>
formula weight	346.43
crystal color, habit	colorless, needle
crystal dimensions (mm)	0.450 × 0.100 × 0.050
no. of reflections used for unit cell determination (2θ range)	15 (30.7–48.5°)
θ scan peak width at half-height	0.54
lattice parameters	
a	10.29 (1) Å
b	21.86 (3) Å
c	8.39 (2) Å
V	1888 (4) Å <sup>3</sup>
space group	P2 <sub>1</sub> 2 <sub>1</sub> 2 <sub>1</sub>
R	0.0630
Z value	4
D <sub>calc</sub>	1.219 g/cm <sup>3</sup>
F000	736
μ (CuKα)	5.90 cm <sup>-1</sup>
Intensity Measurements	
diffractometer	Rigaku AFC5R
radiation	Cu Kα (λ = 1.54178 Å)
temperature	23 °C
attenuators	Zr foil (factors: 3.7, 13.1, 46.6)
take-off angle	6.0°
detector aperture	6.0 mm horizontal 6.0 mm vertical
crystal to detector distance	40 cm
scan type	ω - 2θ
scan rate	8.0°/min
scan width	1.37° = 0.30 tan θ
2θ <sub>max</sub>	119.9°
no. of reflections	1646

**1-Aza-4-oxo-1-(4-phenylbutyl)bicyclo[3.2.1]octane (56)** was prepared by alkylation of 12 with 1-bromo-4-phenylbutane as described in method B and isolated as its hydrochloride salt in 56% yield; mp 178–180 °C (2-propanol). Anal. (C<sub>17</sub>H<sub>23</sub>NO·HCl) C, H, N.

**11-(4-Phenylbutyl)-5,6,7,8,9,10-hexahydro-5-methyl-7,10-iminocyclo[b]indole (34)** was prepared by treatment of amine 56 to the conditions described in method A using *N*-methyl-*N*-phenylhydrazine (Table VIII).

**Method D.** 11-[2-[(3,4-Dichlorophenyl)methyl]-*N*-methylcarboxamido]ethyl]-5,6,7,8,9,10-hexahydro-7,10-iminocyclo[b]indole (47). To a suspension of 13 in anhydrous methylene chloride (20 mL) at 0 °C were added *N*-(*tert*-butoxycarbonyl)-glycine (1.0 g, 5.7 mmol), 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (1.09 g, 5.7 mmol), and 4-(dimethylamino)pyridine (40 mg). After the reaction was allowed to slowly warm to ambient temperature while stirring overnight, it was poured into water (30 mL) and extracted with ethyl acetate (100 mL). The organic extract was washed with brine, dried over magnesium sulfate, filtered, and concentrated. The resulting oil was chromatographed (flash silica, ethyl acetate/hexanes, 50:50) to afford 57 as a white solid: yield 1.38 g (77%); mp 213.5–214.5 °C (ethyl acetate). Anal. (C<sub>20</sub>H<sub>25</sub>N<sub>3</sub>O<sub>3</sub>) C, H, N.

To a suspension of 57 (1.17 g, 3.2 mmol) in anhydrous THF (25 mL) at 0 °C was slowly added 15 mL of a 1 M solution of lithium aluminum hydride in THF over 10 min. The reaction was allowed to warm to room temperature and then heated to reflux for 2 h. The reaction was cooled to 0 °C, and then added sequentially were 1 mL of water, 1 mL of 10% aqueous NaOH, and 1 mL of water. The salts were filtered and washed with warm THF (100 mL), and the solvent was evaporated. Water was azeotroped using benzene to afford 58 as a yellow oil: yield 796 mg (98%); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.50–1.95 (3 H, m), 2.10–2.41 (3 H, m), 2.45 (3 H, s), 2.55–2.75 (4 H, m), 3.3 (1 H, m), 3.65 (1 H, bs), 4.30 (1 H, bs), 7.10–7.50 (4 H, m), 8.42 (1 H, bs).

Diamine 58 was dissolved in anhydrous methylene chloride (5 mL) containing triethylamine (2 equiv) and the solution was added to a solution of 3,4-dichlorophenylacetyl chloride (1.2 equiv, prepared from the corresponding acid and oxalyl chloride in methylene chloride). After being stirred for 1 h, the reaction was

poured into 10% aqueous NaOH (25 mL) and methylene chloride (100 mL). The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated. Chromatography (flash silica, CH<sub>3</sub>OH/CH<sub>2</sub>Cl<sub>2</sub>, 5:95) afforded a white foam; yield 810 mg (97%). An oxalate was prepared in THF (Table VIII).

**Method E.** 2-Fluoro-11-(3-phthalimidopropyl)-5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indole Oxalate (45). To a solution of alcohol 20 (630 mg, 2.30 mmol, prepared according to method B) was added phthalimide (340 mg, 2.31 mmol), triphenylphosphine (665 mg, 2.54 mmol), and anhydrous THF (20 mL), followed by the slow addition of diethyl azodicarboxylate (442 mg, 2.54 mmol). The reaction was stirred for 12 h, poured into methylene chloride (100 mL), and extracted with water (25 mL). The organic layer was separated and dried over anhydrous sodium sulfate and filtered and the solvent removed in vacuo. The crude product was chromatographed (flash silica, CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 9:1) to afford a foam; yield 760 mg (82%). An oxalate was prepared in 2-propanol (Table VIII).

**11-(2-Phthalimidoethyl)-5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indole (43)** was prepared using alcohol 59 (method B, 37%) according to method E in 68% yield and converted into an oxalate (Table VII).

**Method F.** 2-Fluoro-11-(3-isoindolylpropyl)-5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indole Oxalate (46). To a solution of 45 (390 mg, 0.97 mmol) in anhydrous THF (5 mL) was slowly added a 1 M solution of lithium aluminum hydride in THF (4.5 mL). The reaction was heated to reflux for 3 h then allowed to cool to room temperature and treated sequentially with water (0.2 mL), 1 N NaOH (0.2 mL), and water (0.2 mL). After the reaction was stirred for 10 min, the resulting precipitate was filtered and washed with THF (20 mL). The solvent was evaporated in vacuo and the resulting oil chromatographed (flash silica, MeOH/CH<sub>2</sub>Cl<sub>2</sub>, 5:95) to afford a white foam: yield 320 mg (88%). An oxalate was prepared in ethanol using 2 equiv of oxalic acid (Table VIII).

**Method G.** 11-[2-(3,4-Dichlorophenoxy)ethyl]-5,6,7,8,9,10-hexahydro-7,10-iminocyclo[b]indole (30). To a suspension of 3,4-dichlorophenoxyacetic acid (1.34 g, 6.05 mmol) in methylene chloride (10 mL) at 0 °C was slowly added oxalyl chloride (922 mg, 7.26 mmol). The reaction was allowed to warm to room temperature and stirred for another 2 h. Volatiles were removed under vacuum to afford the acid chloride as a yellow oil. To a suspension of 13 (1.0 g, 5.04 mmol) in methylene chloride (10 mL) at 0 °C was added triethylamine (765 mg, 7.56 mmol) followed by the previously prepared acid chloride in methylene chloride (10 mL). After the reaction was stirred for 1 h, it was poured into aqueous sodium bicarbonate (25 mL) and methylene chloride (75 mL). The organic layer was separated, dried over anhydrous sodium sulfate, and filtered, and the solvent removed under reduced pressure. Purification by flash chromatography (ethyl acetate/hexane, 50:50) afforded 11-[2-(3,4-dichlorophenoxy)-1-oxoethyl]-5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indole (60) as a white solid: yield 1.37 g (68%); mp 198.5–199.5 °C (ethyl acetate). Anal. (C<sub>21</sub>H<sub>18</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>2</sub>) C, H, N.

To a solution of 60 (500 mg, 1.25 mmol) in THF (6 mL) was added 8 mL of a 0.66 M solution of AlH<sub>3</sub> in THF.<sup>25</sup> After 15 min, the reaction mixture was poured into 10% aqueous sodium hydroxide (25 mL) and extracted with ethyl acetate (2 × 100 mL). The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated to afford a brown oil: yield 426 mg (88%). A fumarate was prepared in acetone as a white crystalline solid (Table VIII).

**Resolution of (+)-5,6,7,8,9,10-Hexahydro-7,10-iminocyclohept[b]indole (13).** To a solution of L-tartaric acid (41.1 mmol) in water (45 mL) was added (±)-13 (8.15 g, 41.1 mmol). The mixture was heated until a homogeneous solution was formed. The solution was allowed to stand at room temperature for 18 h. The resulting crystalline tartrate (4.8 g) was filtered and washed with 20 mL of water. This material was recrystallized three times from water (4 mL/g) to a constant rotation: [α]<sub>D</sub><sup>25</sup> -7.10° (c = 1.1, H<sub>2</sub>O). The free base was regenerated from an aqueous solution of the salt with excess ammonium hydroxide and extracted with 2% methanol in methylene chloride. The solvent was evaporated to afford 890 mg of crystalline (-)-13: mp 215–216 °C; [α]<sub>D</sub><sup>25</sup> -40.0° (c = 1, MeOH). The optical purity of (-)-13 was estimated by first preparing the *O*-methylmande-



loylamides using (*R*)-(+)-methoxyphenylacetic acid according to the procedure described in method H and observing the ratios of the diastereomeric amides by HPLC, which revealed an enantiomeric excess of >98% ee.

The combined mother liquors of the above tartrate were stirred in the presence of ammonium hydroxide (100 mL) and extracted with 2% methanol in methylene chloride (500 mL). The organic layer was separated, dried over anhydrous sodium sulfate, and filtered to afford 7.1 g of free base. The free base (35.8 mmol) was dissolved in a solution of warm D-tartaric acid (5.37 g, 35.8 mmol) in water (20 mL). The solution was allowed to stand at room temperature for 24 h and the precipitate filtered to afford 8 g of tartrate. This material was recrystallized three times to a constant rotation:  $[\alpha]_D^{24} +7.14^\circ$  ( $c = 1.0$ , H<sub>2</sub>O). The free base was regenerated with aqueous ammonium hydroxide and extracted with 2% methanol in methylene chloride (400 mL). The solvent was evaporated to afford 600 mg of crystalline (+)-13: mp 215–216 °C;  $[\alpha]_D^{24} +40.4^\circ$  ( $c = 1$ , MeOH). The enantiomeric excess was estimated to be >99% using procedure described in method H.

**Method H. Preparation and Isolation of (7*R*,10*S*, $\alpha$ *R*)- and (7*S*,10*R*, $\alpha$ *R*)-11-( $\alpha$ -Methoxy- $\alpha$ -phenylacetyl)-5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[*b*]indoles (61 and 62).** To a stirred solution of ( $\pm$ )-13 (2.50 g, 12.6 mmol) and of (*R*)-(-)-( $\alpha$ -methoxyphenylacetic acid (2.31 g, 13.9 mmol; Aldrich; 99.5  $\pm$  0.5% optically pure) in 100 mL of methylene chloride was added of 1-hydroxybenzotriazole hydrate (1.72 g, 12.7 mmol) followed by 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide (2.44 g, 12.7 mmol). The mixture was allowed to warm to room temperature, stirred overnight, diluted with methylene chloride, washed with water, and dried over anhydrous sodium sulfate. The solvent was removed at reduced pressure and the resulting material was chromatographed on silica gel eluting with methylene chloride followed by 2% methanol in methylene chloride to afford the desired amide (3.56 g, 82%) as a mixture of diastereomers. The diastereomeric amides were dissolved in acetonitrile and separated using preparatory HPLC (reverse phase, C<sub>18</sub>, 40% acetonitrile/60% water). Fractions containing pure diastereomeric amides were combined and isolated separately, by evaporating off most of the acetonitrile followed by extraction with methylene chloride. In each case, the organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated to afford 1.06 g of the pure early eluting amide, 61 [ $t_R$  = 16.9 min;  $[\alpha]_D^{24} +40.4^\circ$  ( $c = 1.1$ , CH<sub>2</sub>Cl<sub>2</sub>); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>)  $\delta$  1.53–1.66 (1 H, m), 1.75–2.15 (3 H, m), 2.52, 2.56 (1 H, app s, rotamers), 2.94, 3.12 (1 H, dd,  $J = 16.2$ , 4.5 Hz), 3.13, 3.28 (3 H, s, rotamers), 4.89 (1 H, m), 5.11, 5.16 (1 H, s, rotamers), 5.55, 5.80 (1 H, d,  $J = 5.2$  Hz, rotamers), 6.92–7.48 (9 H, complex m), 10.67, 10.81 (1 H, s, rotamers); IR (CHCl<sub>3</sub>) 3471, 3006, 1632, 1453 cm<sup>-1</sup> and 1.3 g of the pure late eluting amide, 62 [ $t_R$  = 19.4 min;  $[\alpha]_D^{24} -96.0^\circ$  ( $c = 1.1$ , CH<sub>2</sub>Cl<sub>2</sub>); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>)  $\delta$  1.54–1.63 (1 H, m), 1.76–1.92 (2 H, m), 2.07–2.10 (1 H, m), 2.41–2.59 (1.5 H, complex m), 3.04, 3.29 (3 H, s, rotamers), 3.27 (0.5 H, dd,  $J = 16.2$ , 4.2 Hz, rotamers), 4.79, 4.83 (1 H, m, rotamers), 5.06, 5.14 (1 H, s, rotamers), 5.63 (1 H, m), 6.91–6.99 (2 H, m), 7.17–7.52 (7 H, m), 10.71, 10.82 (1 H, s, rotamers); IR (CHCl<sub>3</sub>) 3469, 3006, 1653, 1463, 1329 cm<sup>-1</sup>. Each of the purified amides showed a diastereomeric excess >99%. An analytical sample of the late eluting amide 62 for X-ray analysis was prepared by recrystallization from acetonitrile: mp 204–205 °C (CH<sub>3</sub>CN). Anal. (C<sub>22</sub>H<sub>22</sub>N<sub>2</sub>O<sub>2</sub>) C, H, N.

**X-Ray Crystallographic Analysis.** The absolute configuration of (+)-13 was indirectly determined by an X-ray analysis of its *N*-11-(*O*-methylmandelic acid) derivative, 62. A colorless needle-shaped crystal of C<sub>22</sub>H<sub>22</sub>N<sub>2</sub>O<sub>2</sub> having approximate dimensions of 0.450  $\times$  0.100  $\times$  0.050 mm was mounted on a glass fiber. All measurements were made on a Rigaku AFC5R diffractometer with graphite-monochromated Cu K $\alpha$  radiation and a 12KW rotating-anode generator. Cell constants and an orientation matrix for data collection, obtained from a least-squares refinement using the setting angles of 15 carefully centered reflections in the range 30.70° < 2 $\theta$  < 48.50° corresponded to an orthorhombic cell with dimensions:  $a = 10.29$  (1) Å;  $b = 21.86$  (3) Å;  $c = 8.39$  (2) Å;  $V = 1888$  (4) Å<sup>3</sup>. The space group was determined to be *P*<sub>2</sub><sub>1</sub><sup>2</sup><sub>1</sub><sup>2</sup>. A total of 1646 reflections were collected. The structure was solved by direct methods.<sup>30</sup>

The non-hydrogen atoms were refined either anisotropically or isotropically. The hydrogen atoms were either refined isotropically or included in the structure factor calculation in idealized positions ( $d_{C-H} = 0.95$  Å). The standard deviation of an observation of unit weight was 2.74. The cell parameters and characteristics are given in Table IX.

**Radioligand Binding ( $\sigma$  Assay).** The  $\sigma$  ligand binding studies were determined by competition studies using [<sup>3</sup>H]DTG or [<sup>3</sup>H]-(+)-3-PPP as previously described in detail.<sup>33</sup> Both assays were performed with frozen guinea pig brains, which were thawed and homogenized in 10 volumes (w/v) of ice cold 0.32 M sucrose using a motor-driven glass-fitted Teflon pestle adjusted to 600 rpm. The homogenate was centrifuged at 900g for 10 min (4 °C) and the resultant supernatant collected and centrifuged at 22000g for 20 min. The pellet obtained from the centrifugation was resuspended in 10 volumes of 50 mM Tris-HCl (pH 7.4, 25 °C) and incubated for 30 min at 37 °C. Following the preincubation, the homogenate was centrifuged at 22000g for 20 min and the final pellet was resuspended in the buffer solution to a protein concentration of 0.5–1.0 mg/mL for use in the assay.

The binding reactions were initiated by the addition of tissue (800  $\mu$ M) to tubes containing the assay buffer, the radioligand (final concentration 1–3 nM), and the compound of interest. Final assay volume was 1 mL. Reactions were allowed to proceed for 45 min at 25 °C and terminated by rapid filtration. Filter-bound radioactivity was quantified using conventional liquid scintillation spectrometry at 55% efficiency. Specific binding was typically in the range of 70–90%. For determination of equilibrium dissociation constants ( $K_d$ ), a fixed concentration of radioligand was incubated in the presence of unlabeled ligand ranging in concentration between 0.5 and 10 000 nM. The concentration of test compound causing 50% inhibition of radioligand binding (IC<sub>50</sub>) was determined from concentration–response curves in which at least 14 concentrations of test compounds were examined. All assays were performed using duplicate determinations unless otherwise stated. For comparison purposes, IC<sub>50</sub> values are reported rather than  $K_i$  values.

**Dopamine D<sub>2</sub> Assay.** The affinity of compounds of interest for the D<sub>2</sub> receptor was determined according to a previously reported method.<sup>38</sup> Briefly, on the day of the assay, rats were sacrificed by decapitation, the corpus striatum was dissected and homogenized in 20 volumes of 50 mM Tris-HCl (pH 7.5, 25 °C). The homogenate was centrifuged (4 °C) and the resulting pellet was resuspended in 20 volumes of fresh buffer containing 100 mM NaCl to a tissue concentration of 3.75 mg wet weight/mL. A portion of the suspension (800  $\mu$ L) was added in triplicate to the tubes containing 3 nM [<sup>3</sup>H]sulpiride and the test compound. The final assay volume was 1 mL; haloperidol (10  $\mu$ M) was used to determine nonspecific binding. Following a 60-min incubation at 25 °C, the reactions were terminated by rapid filtration over Whatman GF/B filters which had been pretreated in a solution of 0.3% (w/v) of aqueous polyethyleneimine. Filters were washed three times using 5 mL of cold buffer and processed using standard procedures to determine radioactivity. IC<sub>50</sub> values were obtained from concentration–response curves in which a number of concentrations of the test compound were examined.  $K_i$  values were determined using the Cheng–Prusoff equation.<sup>39</sup>

## References

- (1) For a recent review, see: (a) Walker, J. M.; Bowen, W. D.; Walker, F. O.; Matsumoto, R. R.; De Costa, B.; Rice, K. C. *Sigma Receptors: Biology and Function*. *Pharmacol. Rev.* 1990, 42, 355–402. (b) Kaiser, C.; Pontecorvo, M. J.; Mewshaw, R. E. *Sigma Receptor Ligands: Function and Activity*. *Neurotransmissions* 1991, VII, 1–5.
- (2) Walker, J. M.; Matsumoto, R. R.; Bowen, W. D.; Gans, D. L.; Jones, K. D.; Walker, F. O. Evidence for a Role of Haloperidol-Sensitive  $\sigma$ -Opiate Receptors in the Motor Effects of Antipsychotic Drugs. *Neurology* 1988, 38, 961–965.
- (3) Bowen, W. D.; Walker, J. M.; Yashar, A. G.; Matsumoto, R. R.; Walker, F. O.; Lorden, J. F. Altered Haloperidol-Sensitive  $\sigma$  Receptors in the Genetically Dystonic (dt) Rat. *Eur. J. Pharmacol.* 1988, 147, 153–154.
- (4) Campbell, B. G.; Bobker, D. H.; Leslie, F. M.; Mefford, I. N.; Wever, E. Both the  $\sigma$  Receptor-Specific Ligand (+)3-PPP and the PCP Receptor-Specific Ligand TCP Act in the Mouse Vas Deferens via Augmentation of Electrically Evoked Norepinephrine Release. *Eur. J. Pharmacol.* 1987, 138, 447–449.

- (5) Vaupel, D. B.; Su, T. P. Guinea-Pig Vas Deferens Preparation May Contain Both Sigma Receptors and Phencyclidine Receptors. *Eur. J. Pharmacol.* 1987, 139, 125-128.
- (6) Bowen, W. D.; Kirschner, B. N.; Newman, A. H.; Rice, K. C.  $\sigma$  Receptors Negatively Modulate Agonist-Stimulated Phosphoinositide Metabolism in Rat Brain. *Eur. J. Pharmacol.* 1988, 149, 399-400.
- (7) Ceci, A.; Smith, M.; French, E. D. Activation of the A<sub>10</sub> Mesolimbic System by the  $\sigma$ -Receptor Agonist (+)SKF 10,047 Can Be Blocked by Rimcazole, a Novel Putative Antipsychotic. *Eur. J. Pharmacol.* 1988, 154, 53.
- (8) Matsumoto, R. R.; Walker, J. M. Inhibition of Rubral Neurons by a Specific Ligand for  $\sigma$  Receptors. *Eur. J. Pharmacol.* 1988, 158, 161-165.
- (9) Martin, W. R.; Eades, C. G.; Thompson, J. A.; Huppler, R. E.; Gilbert, P. E. The Effects of Morphine and Nalorphine-Like Drugs in the Nondependent and Morphine-Dependent Chronic Spinal Dog. *J. Pharmacol. Exp. Ther.* 1976, 197, 517-532.
- (10) Schwarcz, G.; Halaris, A.; Dren, A.; Manberg, P. Open Label Evaluation of the Novel Antipsychotic Compound BW234U in Chronic Schizophrenics. *Drugs Dev. Res.* 1985, 5, 387-393.
- (11) Wadworth, A. N.; Heel, R. C. Remoxipride. A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential in Schizophrenia. *Drugs* 1990, 40, 863-879.
- (12) Taylor, D. P.; Dekleva, J. Potential Antipsychotic BMY 14802 Selectively Binds to Sigma Sites. *Drug Dev. Res.* 1987, 11, 65-70.
- (13) Jain, A. K.; Kelwala, S.; Moore, N.; Gershon, S. A. Controlled Clinical Trial of Tiospirone in Schizophrenia. *Int. Clin. Psychopharmacol.* 1987, 2, 129-133.
- (14) Su, T.-P. HR 375: A Potential Antipsychotic Drug that Interacts with Dopamine D<sub>2</sub> Receptors and  $\sigma$ -Receptors in the Brain. *Neurosci. Lett.* 1987, 71, 224.
- (15) (a) Abou-Gharbia, M.; Patel, U. R.; Webb, M. B.; Moyer, J. A.; Andree, T. H.; Muth, E. A. Antipsychotic Activity of Substituted  $\gamma$ -Carbolines. *J. Med. Chem.* 1987, 30, 1818-1823. (b) Abou-Gharbia, M.; Andree, T. Wy-47384. *Drugs Future* 1988, 13, 541-542.
- (16) Erickson, R.; Natalie, K. J. Jr.; Bock, W.; Lu, Z.; Farzin, F.; Sherrill, R. G.; Meloni, D. J.; Patch, R. J.; Rzeszutarski, W. J.; Clifton, J.; Pontecorvo, M. J.; Bailey, M. A.; Naper, K.; Karbon, W. (Aminoalkoxy)chromones. Selective  $\sigma$  Receptor Ligands. *J. Med. Chem.* 1992, 35, 1526-1535.
- (17) Karbon, E. W.; Abreu, M. E.; Erickson, R.; Clissold, D.; Pontecorvo, M. J.; Witkin, J. M.; Katz, J. L.; Ferkany, J. W. Biochemical, Neurochemical and Behavioral Profile of Aminoalkoxychromones, Potent and Selective Ligands for Sigma Sites. In *Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neuromodulation and Neuroprotection?* Kamenka, J. M.; Domino, E. F., Eds.; NPP Books: Ann Arbor, MI, 1992; pp 75-97.
- (18) Largent, B. L.; Wikstrom, H.; Snowman, A. M.; Snyder, S. H. Novel Antipsychotic Drugs Share High Affinity for  $\sigma$  Receptors. *Eur. J. Pharmacol.* 1987, 155, 345-347.
- (19) Snyder, S. H.; Largent, B. L. Receptor Mechanisms in Antipsychotic Drug Action: Focus on Sigma Receptors. *J. Neuropsychiatry* 1989, 1, 7-15.
- (20) Largent, B. L.; Wikstrom, H.; Gundlach, A. L.; Snyder, S. H. Structural Determinants of  $\sigma$  Receptor Affinity. *Mol. Pharmacol.* 1987, 32, 772-784.
- (21) (a) Glennon, R. A.; Ismaiel, A. M.; Smith, J. D.; Yousif, M.; El-Ashmawy, M.; Herndon, J. L.; Fischer, J. B.; Burke Howie, K. J.; Server, A. C. Binding of Substituted and Conformationally Restricted Derivatives of *N*-(3-Phenyl-n-propyl)-1-phenyl-2-aminopropane at  $\sigma$ -Receptors. *J. Med. Chem.* 1991, 34, 1855-1859. (b) Glennon, R. A.; Smith, J. D.; Ismaiel, A. M.; El-Ashmawy, M.; Battaglia, G.; Fisher, J. B. Identification and Exploitation of the  $\sigma$ -Opiate Pharmacophore. *J. Med. Chem.* 1991, 34, 1094-1098.
- (22) Manallack, D. T.; Wong, M. G.; Costa, M.; Andrews, P. R.; Beart, P. M. Receptor Site Topographies for Phencyclidine-Like and  $\sigma$  Drugs: Predictions from Quantitative Conformational, Electrostatic Potential, and Radioreceptor Analyses. *Mol. Pharmacol.* 1988, 34, 863-879.
- (23) (a) Montzka, T. A.; Matiskella, J. D.; Partyka, R. A. 2,2,2-Trichloroethyl Chloroformate: A General Reagent for Demethylation of Tertiary Methylamines. *Tetrahedron Lett.* 1974, 1325-1327. (b) Kraiss, G.; Nador, K. A. Convenient Synthesis of Nortropine from Tropine or Tropinone. *Tetrahedron Lett.* 1971, 57-58.
- (24) Robinson, B. Recent Studies on the Fischer Indole Synthesis. *Chem. Rev.* 1969, 69, 227-250.
- (25) de Costa, B. R.; Rice, K. C.; Bowen, W. D.; Thurkauf, A.; Rothman, R. B.; Band, L.; Jacobson, A. E.; Radesca, L.; Contreras, P. C.; Gray, N. M.; Daly, I.; Iyengar, S.; Finn, D. T.; Vazirani, S.; Walker, J. M. Synthesis and Evaluation of *N*-Substituted *cis*-*N*-Methyl-2-(1-pyrrolidinyl)cyclohexylamines as High Affinity  $\sigma$  Receptor Ligands. Identification of a New Class of Highly Potent and Selective  $\sigma$  Receptor Probes. *J. Med. Chem.* 1990, 33, 3100-3110.
- (26) Helmchen, G.; Strubert, W. Determination of Optical Purity by High Performance Liquid Chromatography. *Chromatography* 1974, 7, 713-715.
- (27) It should be mentioned that attempts to cleave amides 61 and 62 were unsuccessful using either potassium *tert*-butoxide/H<sub>2</sub>O/THF<sup>28</sup> or Superhydride.<sup>29</sup> However, 61 could be cleaved in modest yields using methyllithium in THF at 0 °C, though 62 again could not be cleaved.
- (28) Gassman, P. G.; Hodgson, P. K. G.; Balchunis, R. J. Base-Promoted Hydrolysis of Amides at Ambient Temperatures. *J. Am. Chem. Soc.* 1976, 98, 1275.
- (29) Mellin, C.; Vallgård, J.; Nelson, D. L.; Björk, L.; Yu, H.; Andén, N.-E.; Csöregi, I.; Arvidsson, L.-E.; Hacksell, U. A 3-D Model for 5-HT<sub>1A</sub>-Receptor Agonists Based on Stereoselective Methyl-Substituted and Conformationally Restricted Analogues of 8-Hydroxy-2-(dipropylamino)tetralin. *J. Med. Chem.* 1991, 34, 497-510.
- (30) Gilmore, C. J. MITHRIL-An Integrated Direct Methods Computer Program. *J. Appl. Crystallogr.* 1984, 17, 42-46.
- (31) Hellewell, S. B.; Bowen, W. D. A Sigma-like Binding Site in Rat Pheochromocytoma (PC12): Decreased Affinity for (+)-Benzomorphans and Lower Molecular Weight Suggest a Different Sigma Receptor Form from That of Guinea Pig Brain. *Brain Res.* 1990, 527, 244-253.
- (32) Hellewell, S. B.; Bruce, A. E.; Bowen, W. D. Characterization of "Sigma-Like" Binding Sites in Rat Liver Membranes: Further Evidence for Sigma-1 and Sigma-2 Sites. In *New Leads in Opioid Research, Proceedings of the International Narcotics Research Conference*; van Ree, J. M.; Mulder, A. H.; Wiegant, V. M., van Wimersma Greidanus, T. B., Eds.; International Congress Series No. 914; Excerpta Medica-Elsevier: Amsterdam, 1990; pp 270-271.
- (33) Karbon, E. W.; Naper, K.; Pontecorvo, M. J. [<sup>3</sup>H]DTG and [<sup>3</sup>H]-(+)-3-PPP Label Pharmacologically Distinct  $\sigma$  Binding Sites in Guinea Pig Brain Membranes. *Eur. J. Pharmacol.* 1991, 193, 21-27.
- (34) Itzhak, Y.; Stein, I. Sigma Binding Sites in the Brain; An Emerging Concept for Multiple Sites and Their Relevance for Psychiatric Disorders. *Life. Sci.* 1990, 47, 1073-1081.
- (35) Itzhak, Y.; Stein, I. Regulation of  $\sigma$  Receptors and Responsiveness to Guanine Nucleotides Following Repeated Exposure of Rats to Haloperidol: Further Evidence for Multiple  $\sigma$  Binding Sites. *Brain Res.* 1991, 566, 166-172.
- (36) Quirion, R.; Bowen, W. D.; Itzhak, Y.; Junien, J. L.; Musachio, J. M.; Rothman, R. B.; Su, T.-P.; Tam, S. W.; Taylor, D. P. A Proposal for the Classification of Sigma Binding Sites. *Trends Pharmacol. Sci.* 1992, 13, 85-86 and references cited.
- (37) Rothman, R. B.; Reid, A.; Mahboubi, A.; Kim, C.-H.; De Costa, B. R.; Jacobson, A. E.; Rice, K. C. Labeling by [<sup>3</sup>H]1,3-Di(2-tolyl)-guanidine of Two High Affinity Binding Sites in Guinea Pig Brain: Evidence for Allosteric Regulation by Calcium Channel Antagonists and Pseudoallosteric Modulation by  $\sigma$  Ligands. *Mol. Pharmacol.* 1991, 39, 222-232.
- (38) Imatuku, J. The Characterization of [<sup>3</sup>H]-Sulpiride Binding Sites in Rat Striatal Membranes. *Brain Res.* 1987, 402, 331-338.
- (39) Cheng, Y. C.; Prusoff, W. H. Relationship Between the Inhibition Constant (K<sub>i</sub>) and the Concentration of Inhibitor Which Causes 50 Percent Inhibition (IC<sub>50</sub>) of an Enzymatic Reaction. *Biochem. Pharmacol.* 1973, 22, 3099-3108.
- (40) Furan and thiazole were deprotonated according to ref 41 and alkylated with dibromobutane to provide the respective side chain alkylating agents used in method B.
- (41) Brandsma, L.; Verkruijsse, H. D. *Preparative Polar Organometallic Chemistry 1*; Springer-Verlag: Berlin, 1987; Vol. 1, pp 222-224.